Cloudflare Inc vs Vaxcyte Inc. Common Stock — how do they compare? Cloudflare Inc trades at $318.41 (market cap $123.81B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Cloudflare Inc is far larger — about 11.8× Vaxcyte Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is more actively traded (2,644,694 versus 1,745,042). Which is the better fit depends on your goals — on Pluang, investors hold Cloudflare Inc for 61 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| NET | PCVX | |
|---|---|---|
Market Cap | $123.81B | $10.51B |
Volume | 1,745,042 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $361.00 | $73.82 |
52-Week Low | $160.16 | $40.32 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | $123.18B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
Cloudflare (NET) trades at $324.01, down 7.6% over 24 hours, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $328. Fundamentally, revenue growth is strong, reaching $2.17B in 2025, but profitability remains a challenge with a net income margin of -8.21%. Recent news highlights product launches like Cloudflare Basin and a partnership with Deutsche Telekom, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst consensus and strategic initiatives, but high valuation multiples and persistent losses pose risks. Investment opportunity lies in continued top-line expansion and market share gains, while key risks include competitive pressures and execution on path to profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →